Clinical trials of anti-TNF therapy have shown little beneficial impact in acute inflammatory diseases such as sepsis or ARDS despite ample preclinical evidence of TNF involvement in their pathophysiology (18). This evidence concerns the gene TNF and acute respiratory distress syndrome.